Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor

Molecular Therapy Oncolytics

Volumn 1, Issue , 2014, Pages 14003-

  Lo, Agnes Shuk Yee ^a,b,c   Xu, Chen ^a,b,d   Murakami, Akikazu ^a,b,e   Marasco, Wayne A ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d Beijing Tri prime Genetic Engineering Corporation Limited   (China)

^e UNIVERSITY OF THE RYUKYUS   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARBONATE DEHYDRATASE IX; CHIMERIC ANTIGEN RECEPTOR; INTERLEUKIN 2; LENTIVIRUS VECTOR; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY;

3T3 CELL LINE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY RESPONSE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL KILLING; CELL THERAPY; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MEGADOSE; EMBRYO; FEMALE; GENETIC TRANSDUCTION; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SPLEEN; T LYMPHOCYTE; TISSUE NECROSIS;

EID: 85006118741     PISSN: None     EISSN: 23727705     Source Type: Journal    
DOI: 10.1038/mto.2014.3     Document Type: Article

References (50)

1. Ivanov, S, Liao, SY, Ivanova, A, Danilkovitch-Miagkova, A, Tarasova, N, Weirich, G et al. (2001). Expression of hypoxia-inducible cell-surface transmembrane carbonic anhydrases in human cancer. Am J Pathol 158: 905-919.
2. Loncaster, JA, Harris, AL, Davidson, SE, Logue, JP, Hunter, RD, Wycoff, CC et al. (2001). Carbonic anhydrase (CA IX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399.
3. Hilvo, M, Baranauskiene, L, Salzano, AM, Scaloni, A, Matulis, D, Innocenti, A et al. (2008). Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes. J Biol Chem 283: 27799-27809.
4. Oosterwijk, E, Ruiter, DJ, Hoedemaeker, PJ, Pauwels, EK, Jonas, U, Zwartendijk, J et al. (1986). Monoclonal antibody G 250 recognizes a determinant present in renal-cell carcinoma and absent from normal kidney. Int J Cancer 38: 489-494.
5. Liao, SY, Brewer, C, Zada, J, Pastorek, J, Pastorekova, S, Manetta, A et al. (1994). Identification of the MN antigen as a diagnostic biomarker of cervical intraepithelial squamous and glandular neoplasia and cervical carcinomas. Am J Pathol 145: 598-609.
6. Liao, SY, Aurelio, ON, Jan, K, Zavada, J and Stanbridge, EJ (1997). Identification of the MN/CA9 protein as a reliable diagnostic biomarker of clear cell carcinoma of the kidney. Cancer Res 57: 2827-2831.
7. Atkins, M, Regan, M, McDermott, D, Mier, J, Stanbridge, E, Youmans, A et al. (2005). Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 11: 3714-3721.
8. Lokich, J (1997). Spontaneous regression of metastatic renal cancer. Case report and literature review. Am J Clin Oncol 20: 416-418.
9. Chang, AE, Li, Q, Jiang, G, Sayre, DM, Braun, TM and Redman, BG (2003). Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer. J Clin Oncol 21: 884-890.
10. Dudley, ME, Wunderlich, JR, Robbins, PF, Yang, JC, Hwu, P, Schwartzentruber, DJ et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
11. Schaft, N, Willemsen, RA, de Vries, J, Lankiewicz, B, Essers, BW, Gratama, JW et al. (2003). Peptide fine specificity of anti-glycoprotein 100 CTL is preserved following transfer of engineered TCR alpha beta genes into primary human T lymphocytes. J Immunol 170: 2186-2194.
12. Buben, J (2004). MHC class I down-regulation: tumour escape from immune surveillance (review). Int J Oncol 25: 487-491.
13. Gajewski, TF, Meng, Y, Blank, C, Brown, I, Kacha, A, Kline, J et al. (2006). Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 213: 131-145.
14. Frigola, X, Inman, BA, Lohse, CM, Krco, CJ, Cheville, JC, Thompson, RH et al. (2011). Identification of a soluble form of B7-H1 that retains immunosuppressive activity and is associated with aggressive renal cell carcinoma. Clin Cancer Res 17: 1915-1923.
15. Grin, R, Guyot, M, Giuliano, S, Boncompagni, M, Ambrosetti, D, Chamorey, E et al. (2014). The CXCL7/CXCR1/2 axis is a key driver in the growth of clear cell renal cell carcinoma. Cancer Res 74: 873-883.
16. Sadelain, M, Brentjens, R and Rivie, I (2009). The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol 21: 215-223.
17. Lamers, CH, Sleijfer, S, van Steenbergen, S, van Elzakker, P, van Krimpen, B, Groot, C et al. (2013). Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther 21: 904-912.
18. Milone, MC, Fish, JD, Carpenito, C, Carroll, RG, Binder, GK, Teachey, D et al. (2009). Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17: 1453-1464.
19. Wilkie, S, Picco, G, Foster, J, Davies, DM, Julien, S, Cooper, L et al. (2008). Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor. J Immunol 180: 4901-4909.
20. Lo, AS, Ma, Q, Liu, DL and Junghans, RP (2010). Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin Cancer Res 16: 2769-2780.
21. Kalos, M, Levine, BL, Porter, DL, Katz, S, Grupp, SA, Bagg, A et al (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Translat Med 3: 73-95.
22. Pegram, HJ, Park, JH and Brentjens, RJ (2014). CD28z CARs and armored CARs. Cancer J 20: 127-133.
23. Xu, C, Lo, A, Yammanuru, A, Tallarico, AS, Brady, K, Murakami, A et al. (2010). Unique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technology. PLoS ONE 5: e9625.
24. Sui, J, Aird, DR, Tamin, A, Murakami, A, Yan, M, Yammanuru, A et al. (2008). Broadening of neutralization activity to directly block a dominant antibody-driven SARS-coronavirus evolution pathway. PLoS Pathog 4: e1000197.
25. Mirzabekov, T, Kontos, H, Farzan, M, Marasco, W and Sodroski, J (2000). Paramagnetic proteoliposomes containing a pure, native, and oriented seven-transmembrane segment protein, CCR5. Nat Biotechnol 18: 649-654.
26. Wald, O, Weiss, ID, Wald, H, Shoham, H, Bar-Shavit, Y, Beider, K et al. (2006). IFN-gamma acts on T cells to induce NK cell mobilization and accumulation in target organs. J Immunol 176: 4716-4729.
27. Zeytin, H, Reali, E, Zaharoff, DA, Rogers, CJ, Schlom, J and Greiner, JW (2008). Targeted delivery of murine IFN-gamma using a recombinant fowlpox virus: NK cell recruitment to regional lymph nodes and priming of tumor-specific host immunity. J Interferon Cytokine Res 28: 73-87.
28. Murugaiyan, G and Saha, B (2009). Protumor vs antitumor functions of IL-17. J Immunol 183: 4169-4175.
29. Bar, E, Whitney, PG, Moor, K, Reis e Sousa, C and LeibundGut-Landmann, S (2014). IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity 40: 117-127.
30. Hinrichs, CS, Kaiser, A, Paulos, CM, Cassard, L, Sanchez-Perez, L, Heemskerk, B et al. (2009). Type 17 CD8+ T cells display enhanced antitumor immunity. Blood 114: 596-599.
31. Hombach, AA, Rappl, G and Abken, H (2013). Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 "superstimulation". Mol Ther 21: 2268-2277.
32. Mor, F and Cohen, IR (1996). IL-2 rescues antigen-specific T cells from radiation or dexamethasone-induced apoptosis. Correlation with induction of Bcl-2. J Immunol 156: 515-522.
33. Isakov, N and Altman, A (2012). PKC-theta-mediated signal delivery from the TCR/CD28 surface receptors. Front Immunol 3: 273.
34. Loskog, A, Giandomenico, V, Rossig, C, Pule, M, Dotti, G and Brenner, MK (2006). Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells. Leukemia 20: 1819-1828.
35. Schwarzer, A, Wolf, B, Fisher, JL, Schwaab, T, Olek, S, Baron, U et al. (2012). Regulatory T-cells and associated pathways in metastatic renal cell carcinoma (mRCC) patients undergoing DC-vaccination and cytokine-therapy. PLoS ONE 7: e46600.
36. Lamers, CH, Willemsen, R, van Elzakker, P, van Steenbergen-Langeveld, S, Broertjes, M, Oosterwijk-Wakka, J et al. (2011). Immune responses to transgene and retroviral vector in patients treated with ex vivo-engineered T cells. Blood 117: 72-82.
37. Miotti, S, Negri, DR, Valota, O, Calabrese, M, Bolhuis, RL, Gratama, JW et al. (1999). Level of anti-mouse-antibody response induced by bi-specific monoclonal antibody OC/TR in ovarian-carcinoma patients is associated with longer survival. Int J Cancer 84: 62-68.
38. Kershaw, MH, Westwood, JA, Parker, LL, Wang, G, Eshhar, Z, Mavroukakis, SA et al. (2006). A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res 12(20 Pt 1): 6106-6115.
39. Pastorekova, S (2004). Carbonic anhydrase IX (CA IX) as a potential target for cancer therapy. Cancer Ther 2: 245-262.
40. Pastorekov S, Parkkila, S, Parkkila, AK, Opavsk, R, Zeln, V, Saarnio, J et al. (1997). Carbonic anhydrase IX, MN/CA IX: analysis of stomach complementary DNA sequence and expression in human and rat alimentary tracts. Gastroenterology 112: 398-408.
41. Saarnio, J, Parkkila, S, Parkkila, AK, Waheed, A, Casey, MC, Zhou, XY et al. (1998). Immunohistochemistry of carbonic anhydrase isozyme IX (MN/CA IX) in human gut reveals polarized expression in the epithelial cells with the highest proliferative capacity. J Histochem Cytochem 46: 497-504.
42. Zada, J, Zadov Z, Zat'ovicov M, Hyrsl, L and Kawaciuk, I (2003). Soluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients. Br J Cancer 89: 1067-1071.
43. Hombach, A, Koch, D, Sircar, R, Heuser, C, Diehl, V, Kruis, W et al. (1999). A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA. Gene Ther 6: 300-304.
44. Carpenito, C, Milone, MC, Hassan, R, Simonet, JC, Lakhal, M, Suhoski, MM et al. (2009). Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains. Proc Natl Acad Sci USA 106: 3360-3365.
45. Gill, S, Tasian, SK, Ruella, M, Shestova, O, Li, Y, Porter, DL et al (2014). Efficacy against human acute myeloid leukemia and myeloablation of normal hematopoiesis in a mouse model using chimeric antigen receptor-modified T cells. Blood 123: 2343-2354.
46. Hombach, AA, Heiders, J, Foppe, M, Chmielewski, M and Abken, H (2012). OX40 costimulation by a chimeric antigen receptor abrogates CD28 and IL-2 induced IL-10 secretion by redirected CD4(+) T cells. Oncoimmunology 1: 458-466.
47. Song, DG, Ye, Q, Carpenito, C, Poussin, M, Wang, LP, Ji, C et al. (2011). In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 71: 4617-4627.
48. Bedke, J and Stenzl, A (2013). Immunotherapeutic strategies for the treatment of renal cell carcinoma: where are we now Expert Rev Anticancer Ther 13: 1399-1408.
49. Bailey, A and McDermott, DF (2013). Immune checkpoint inhibitors as novel targets for renal cell carcinoma therapeutics. Cancer J 19: 348-352.
50. Maher, J, Brentjens, RJ, Gunset, G, Rivie, I and Sadelain, M (2002). Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta/CD28 receptor. Nat Biotechnol 20: 70-75.